Lifecare ASA — Capital/Financing Update 2026

Mar 2, 2026

Lifecare ASA: Commencement of the Exercise Period for Warrants Series 1 issued in connection with the Rights Issue

Lifecare ASA: Commencement of the Exercise Period for Warrants Series 1 issued in connection with the Rights Issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED

STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE

PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement by Lifecare ASA (the

"Company") on 27 February 2026 regarding the exercise price for the

129,000,033 warrants series 1 with ISIN NO0013709196 ("Warrants Series 1")

issued in connection with the partially underwritten rights issue of new

shares in the Company completed in January 2026 (the "Rights Issue").

Each Warrant Series 1 gives the holder a right to subscribe for one new share

in the Company at an exercise price of NOK 0.3342 per share (the "Exercise

Price").

The exercise period for Warrants Series 1 commences at 09:00 hours (CET)

today, 2 March 2026, and expires at 16:30 hours (CET) on 13 March 2026 (the

"Exercise Period").

Warrants Series 1 are listed and tradable on Euronext Oslo Børs under the

ticker code "LIFEJ". The trading in Warrants Series 1 will be halted five days

before the end of the Exercise Period to facilitate settlement of exercised

Warrants Series 1. Warrants Series 1 will thus be tradable until 16:30 hours

(CET) on 6 March 2026.

Warrants Series 1 not sold within 6 March 2026 at 16:30 (CET) or exercised

within 13 March 2026 at 16:30 (CET) will lapse with no compensation to the

holders. Holders of Warrants Series 1 who do not exercise their Warrants

Series 1 within the Exercise Period may experience a dilution of their

shareholding in the Company.

Exercise procedure

Warrants Series 1 are exercised through the submission of a duly completed

exercise form for Warrants Series 1 (the "Exercise Form") to DNB Carnegie, a

part of DNB Bank ASA, or SB1 Markets AS (together, the "Managers") at the

address or email address set out in the Exercise Form within the Exercise

Period or through the VPS online subscription system within the Exercise

Period. The Exercise Form is available at the Managers' websites

www.dnb.no/emisjoner and www.sb1markets.no/transaksjoner. By completing and

submitting an Exercise Form, the holder of Warrants Series 1 irrevocably

undertakes to subscribe for and acquire a number of new shares equal to the

number of Warrants Series 1 exercised at the Exercise Price.

Payment for and delivery of shares

Notification of the total exercise amount to be paid by each subscriber are

expected to be distributed on or about 16 March 2026. The payment for new

shares to be issued to a subscriber as a result of the exercise of Warrants

Series 1 falls due on 19 March 2026 (the "Payment Date").

Subject to timely payment of the aggregate subscription amount for the new

shares to be issued as a result of the exercise of Warrants Series 1 on the

Payment Date, the Company expects that the share capital increase pertaining

to the issuance of the new shares will be registered with the Norwegian

Register of Business Enterprises on or about 25 March 2026 and that shares

will be delivered to the VPS accounts of the subscribers to whom they are

allocated on or about 26 March 2026.

A subscriber's default in timely payment of the aggregate subscription price

for the new shares subscribed by such subscriber may, at the Company's and the

Managers' sole discretion, result in the subscribed new shares not being

issued. In such an event, the exercised Warrants Series 1 may be considered

forfeited and will not give a right to subscribe for new shares.

Financial intermediaries

If Warrants Series 1 are registered through a financial intermediary, the

financial intermediary will customarily give the holder details of the

aggregate number of Warrants Series 1 which it is entitled to exercise. The

relevant financial intermediary will customarily supply each holder with this

information in accordance with its usual customer relations procedures.

Holders of Warrants Series 1 through a financial intermediary should contact

the financial intermediary if they have received no information with respect

to Warrants Series 1.

Listing and commencement of trading in the new shares

The shares received upon exercise of Warrants Series 1 will be listed on

Euronext Oslo Børs under ISIN NO0013355859 and ticker code "LIFE". The shares

will be listed as soon as the new shares are fully paid, the share capital

increase pertaining to the issuance of the new shares has been registered with

the Norwegian Register of Business Enterprises, and the new shares have been

issued in the VPS.

The shares received upon exercise of Warrants Series 1 may not be transferred

or traded before (i) the new shares have been fully paid, (ii) the share

capital increase pertaining to the issuance of the new shares has been

registered with the Norwegian Register of Business Enterprises, and (iii) the

new shares have been issued in the VPS.

Advisors

DNB Carnegie, a part of DNB Bank ASA, and SB1 Markets AS act as managers in

the Rights Issue and the warrants exercise.

Important information

This announcement does not constitute an offer of securities for sale or a

solicitation of an offer to purchase securities of the Company in the United

States or any other jurisdiction. Copies of this announcement may not be sent

to jurisdictions, or distributed in or sent from jurisdictions, in which this

is barred or prohibited by law. The securities of the Company may not be

offered or sold in the United States absent registration or an exemption from

registration under the U.S. Securities Act of 1933, as amended (the "U.S.

Securities Act"). The securities of the Company have not been, and will not

be, registered under the U.S. Securities Act. Any sale in the United States of

the securities mentioned in this communication will be made solely to

"qualified institutional buyers" as defined in Rule 144A under the U.S.

Securities Act. No public offering of the securities will be made in the

United States.

This announcement is an advertisement and is not a prospectus for the purposes

of Regulation (EU) 2017/1129 of the European Parliament and of the Council of

14 June 2017 on prospectuses to be published when securities are offered to

the public or admitted to trading on a regulated market, and repealing

Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the

"Prospectus Regulation").

This announcement is not for publication or distribution in, directly or

indirectly, Australia, Canada, Japan, the United States, or any other

jurisdiction in which such release, publication or distribution would be

unlawful, and it does not constitute an offer or invitation to subscribe for

or purchase any securities in such countries or in any other jurisdiction. In

particular, the document and the information contained herein should not be

distributed or otherwise transmitted into the United States or to publications

with a general circulation in the United States of America.

The Managers are acting for the Company in connection with the Rights Issue

and no one else and will not be responsible to anyone other than the Company

for providing the protections afforded to their respective clients or for

providing advice in relation to the Rights Issue or any transaction or

arrangement referred to in this announcement.

Matters discussed in this announcement may constitute forward-looking

statements. Forward-looking statements are statements that are not historical

facts and may be identified by words such as "anticipate", "believe",

"continue", "estimate", "expect", "intends", "may", "should", "will" and

similar expressions. The forward-looking statements in this release are based

upon various assumptions, many of which are based, in turn, upon further

assumptions. Although the Company believes that these assumptions were

reasonable when made, these assumptions are inherently subject to significant

known and unknown risks, uncertainties, contingencies, and other important

factors which are difficult or impossible to predict and are beyond its

control. Such risks, uncertainties, contingencies, and other important factors

could cause actual events to differ materially from the expectations expressed

or implied in this release by such forward-looking statements. The

information, opinions and forward-looking statements contained in this

announcement speak only as at its date and are subject to change without

notice. This announcement is made by and is the responsibility of the Company.

Neither the Managers nor any of their respective affiliates make any

representation as to the accuracy or completeness of this announcement and

none of them accepts any responsibility for the contents of this announcement

or any matters referred to herein.

This announcement is for information purposes only and is not to be relied

upon in substitution for the exercise of independent judgment. It is not

intended as investment advice and under no circumstances is it to be used or

considered as an offer to sell, or a solicitation of an offer to buy any

securities or a recommendation to buy or sell any securities of the Company.

No reliance may be placed for any purpose on the information contained in this

announcement or its accuracy, fairness, or completeness. Neither the Managers

nor any of their respective affiliates accept any liability arising from the

use of this announcement.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring systems to market. Lifecare

enables osmotic pressure as sensing principle. Lifecare's sensor technology is

suitable for identifying and monitoring the occurrence of a wide range of

analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication, through the

agency of the contact persons set out above, at 2026-03-02 07:00 CET.